How Is Tysabri-Related PML Diagnosed and Monitored?

Latest update (2026-07)

Tysabri (natalizumab) PML injury claims continue to be evaluated based on individual monitoring and diagnosis records. [source]

From General Health Information to Specific Legal Concerns

If you or a loved one is taking Tysabri, you may be concerned about the risk of progressive multifocal leukoencephalopathy (PML). Decades of pharmacovigilance have established that certain immunosuppressive therapies can reactivate the JC virus, leading to this rare but serious brain infection. This page explains the clinical testing and evaluation process used to diagnose and monitor Tysabri-related PML, and what the evidence can and cannot prove.

Understanding Tysabri and Its Association with PML

Tysabri (natalizumab) is a biologic therapy approved as monotherapy for relapsing forms of multiple sclerosis (MS) in adults, including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The drug carries a boxed warning stating that it increases the risk of progressive multifocal leukoencephalopathy (PML), an opportunistic viral infection of the brain that usually leads to death or severe disability (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). PML is caused by reactivation of the John Cunningham virus (JCV) in the central nervous system, leading to demyelination and progressive neurological decline. The boxed warning identifies three key risk factors for PML development: the presence of anti-JCV antibodies, duration of therapy, and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). These factors should be considered in the context of expected benefit when initiating and continuing treatment with Tysabri (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The mechanistic pathway linking Tysabri to PML involves the drug's inhibition of alpha-4 integrin, which prevents lymphocyte trafficking into the brain. This immunosuppressive effect reduces immune surveillance, allowing JCV to replicate unchecked in oligodendrocytes and astrocytes, leading to lytic infection and demyelination.

Clinical Presentation, Diagnosis, and Prognosis of PML

Clinical presentation of PML typically includes subacute onset of focal neurological deficits such as hemiparesis, visual field defects, cognitive impairment, ataxia, and speech difficulties. Diagnosis relies on brain MRI showing multifocal white matter lesions without mass effect, and detection of JCV DNA in cerebrospinal fluid by polymerase chain reaction. The prognosis is poor, with most patients experiencing severe disability or death within months of symptom onset. The adequacy of warnings regarding Tysabri and PML has been a subject of legal scrutiny. The boxed warning explicitly states that Tysabri increases PML risk and that healthcare professionals should monitor patients for any new sign or symptom suggestive of PML, with dosing withheld immediately at the first sign or symptom (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Patients must be enrolled in the TOUCH Prescribing Program, read the Medication Guide, understand the risks, and complete and sign the Patient Enrollment Form (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Pharmacies and infusion centers must be specially certified to dispense or infuse Tysabri (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Despite these measures, questions may arise about whether prescribers adequately communicated the risk to patients, particularly regarding the cumulative risk over time and the impact of prior immunosuppressant use.

Statute of Limitations for Tysabri Claims in Washington

For affected patients in Washington, attorney-related considerations include the statute of limitations for filing a product liability or medical malpractice claim. In Washington, the statute of limitations for personal injury claims is generally three years from the date of injury or from when the injury was discovered or reasonably should have been discovered. For Tysabri-associated PML, the timeline between exposure and documented harm can vary. PML typically develops after prolonged Tysabri use, often exceeding two years of treatment, but cases have been reported after shorter durations. The onset of symptoms may be insidious, and diagnosis may be delayed, complicating the determination of when the injury occurred for legal purposes. FDA adverse-event reports most frequently associated with Tysabri include fatigue, MS relapse, headache, gait disturbance, fall, memory impairment, asthenia, malaise, and balance disorder (https://api.fda.gov/drug/event.json?search=patient.drug.medicinalproduct:TYSABRI). While these are common adverse effects, PML is a distinct and far more serious outcome. The drug also increases the risk of herpes encephalitis and meningitis, with serious, life-threatening, and sometimes fatal cases reported in the postmarketing setting (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The duration of Tysabri treatment prior to herpes infection onset ranged from a few months to several years (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Patients who develop PML after Tysabri therapy may have legal recourse if they can demonstrate that the warnings provided were inadequate or that their healthcare provider failed to properly monitor for PML symptoms. The statute of limitations in Washington requires prompt action, as delays in filing could bar recovery. Affected individuals should consult with an attorney experienced in pharmaceutical litigation to evaluate their specific circumstances, including the date of diagnosis, the duration of Tysabri use, and any prior immunosuppressant exposure.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the statute of limitations for Tysabri-related PML claims in Washington?

In Washington, the statute of limitations for personal injury claims is generally three years from the date of injury or from when the injury was discovered or reasonably should have been discovered. For Tysabri-associated PML, the timeline can vary due to delayed diagnosis, so it is crucial to consult an attorney promptly.

What are the key risk factors for developing PML while on Tysabri?

The boxed warning for Tysabri identifies three key risk factors: the presence of anti-JCV antibodies, duration of therapy (especially beyond two years), and prior use of immunosuppressants. These factors should be considered when assessing the risk of PML (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Tysabri exposure and a confirmed Progressive Multifocal Leukoencephalopathy diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.